Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial

What Was Tested

The paper reports a study of Glatiramer Acetate in the context of multiple sclerosis, published as a randomized controlled trial.

The Evaluate Patient OutComes (EPOC) study assessed physician- and patient-reported outcomes in individuals with relapsing multiple sclerosis who switched directly from injectable disease-modifying therapy (iDMT; glatiramer acetate, intramuscular or subcutaneous interferon beta-1a, or interferon beta-1b) to once-daily, oral fingolimod.

Post hoc analyses evaluated the impact of a switch to fingolimod versus staying on each of the four individual iDMTs.

Who Took Part

The study group was 1053 patients.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

Overall, 1053 patients were randomized 3:1 to switch to fingolimod or remain on iDMT.

The primary endpoint was the change in Treatment Satisfaction Questionnaire for Medication (TSQM) Global Satisfaction score.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Glatiramer Acetate study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The methods mention a period of 6 months.

All outcomes were evaluated after 6 months of treatment.

What Was Measured

The Evaluate Patient OutComes (EPOC) study assessed physician- and patient-reported outcomes in individuals with relapsing multiple sclerosis who switched directly from injectable disease-modifying therapy (iDMT; glatiramer acetate, intramuscular or subcutaneous interferon beta-1a, or interferon beta-1b) to once-daily, oral fingolimod.

Post hoc analyses evaluated the impact of a switch to fingolimod versus staying on each of the four individual iDMTs.

PubMed files the paper under topics including Fingolimod Hydrochloride, Glatiramer Acetate, Immunosuppressive Agents, Interferon beta-1a, Interferon beta-1b and Multiple Sclerosis, Relapsing-Remitting.

What This Means in Plain Language

The paper is a randomized study of Glatiramer Acetate in 1053 patients in people with multiple sclerosis over 6 months.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (BMC neurology), a journal based in England.

More context: the Glatiramer Acetate compound page, Multiple sclerosis research.